Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2025-11-05 Regulatory Filings
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Oxford Nanopore et bioMérieux lancent AmPORE-TB, une solution de séquençage, à usage de recherche uniquement, pour identifier rapidement la tuberculose résistante aux antibiotiques
Regulatory Filings Classification · 95% confidence The document is a press release issued jointly by Oxford Nanopore Technologies and bioMérieux announcing the launch of a new product, 'AmPORE-TB'. It follows the standard format of a corporate press release, including quotes from executives, background information on both companies, and contact details. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a regulatory filing of a specific legal nature. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-11-05 French
Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug resistant-tuberculosis
Regulatory Filings Classification · 95% confidence The document is a press release announcing a partnership and product launch (AmPORE-TB) between Oxford Nanopore Technologies and bioMérieux. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a regulatory filing or a report publication announcement. As it is a general corporate announcement regarding business operations and product development, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate announcements.
2025-11-05 English
Octobre 2025 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a monthly disclosure of the total number of voting rights and shares, as required by Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. This is a standard regulatory disclosure for French listed companies regarding share capital and voting rights, which does not fit into specific categories like 'Share Issue' or 'Major Shareholding' but is a mandatory regulatory filing.
2025-11-04 French
bioMérieux – Information financière du 3ème trimestre 2025
Earnings Release Classification · 100% confidence The document is a quarterly financial update from bioMérieux for the third quarter of 2025. It provides detailed breakdowns of sales growth, organic performance, regional activity, and updated financial guidance. It is not a full annual report (10-K) nor a simple announcement of a report (RPA), but rather the primary release of quarterly financial results. Therefore, it fits the definition of an Earnings Release (ER). 9M 2025
2025-11-04 French
bioMérieux – Third-Quarter 2025 Business Review
Earnings Release Classification · 95% confidence The document is a detailed business review for the third quarter and nine-month period of 2025 for bioMérieux. It provides comprehensive financial data, including sales analysis by application and region, organic growth figures, and updated full-year guidance. It is not a short announcement (it exceeds 30,000 characters) and contains detailed financial tables and management commentary on performance drivers, which aligns with the definition of an Earnings Release (ER) or a detailed quarterly business update. 9M 2025
2025-11-04 English
Septembre 2025 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Share Issue/Capital Change Classification · 95% confidence The document is a monthly disclosure of the total number of voting rights and shares, as required by Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. This type of regulatory disclosure regarding share capital and voting rights does not fit into specific categories like 'Major Shareholding Notification' (which concerns individual shareholders) or 'Share Issue' (which concerns specific capital changes). Therefore, it falls under the general regulatory filing category.
2025-10-02 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.